Core Viewpoint - King’s Ray Biotechnology focuses on "technology-driven" and "global layout" as its core development strategy, aiming for long-term revenue growth and clear growth paths for various segments [1] Group 1: Financial Projections - The company maintains a "buy" rating, predicting revenue for its main business segments to be $939 million, $825 million, and $961 million for 2025-2027, with year-on-year growth rates of 58%, -12%, and 16% respectively [1] - The estimated PS valuation for the main business segment is based on a 6x PS multiple for 2026 revenue, leading to a valuation of 35.2 billion RMB [1] - The fair value of the company's stake in Legend Biotech, a US-listed company, is estimated at 17 billion RMB as of November 20, 2025 [1] Group 2: Strategic Goals - The company aims to be the global leader in biopharmaceuticals (antibody drugs, gene & cell therapy) and synthetic biology services and products [2] - The strategic plan includes solidifying cash flow to support life sciences, biopharmaceutical CRDMO, and synthetic biology, driving profit growth [2] - The long-term revenue target is set at $3 billion by 2035, with an operating profit margin exceeding 20% [2] Group 3: Business Development Focus - The company is focused on ensuring steady growth in its core businesses, particularly in gene & plasmid services, aiming to expand downstream applications [2] - The antibody protein business aims to enhance core competitiveness and capture the non-outsourcing market by providing innovative instruments and solutions [2] - The protein antibody drug CDMO aims to leverage the rebound in China's biotech sector, accumulate more projects, and enhance sales capabilities in Europe and the US [2] Group 4: Growth Strategy - The company seeks to consolidate its business capabilities by transforming mature services into one-stop solutions, accelerating productization for downstream clients [3] - There is a focus on high-margin products in enzyme preparations, particularly in starch sugar, alcohol, and home care sectors [3] - The company is looking for explosive industry opportunities through innovative protein/enzyme preparations and collaborative development of licensed products [3]

Core Insights - The article discusses advancements in the field of cyclic peptide libraries, particularly focusing on the DNA-encoded library technology (DELT) which enhances the screening and discovery of novel cyclic peptides with superior properties [1][2]. Group 1: Technology and Methodology - DELT allows for the rapid construction and screening of large compound libraries by linking specific nucleic acid tags to peptide molecules, providing an efficient and cost-effective platform for high-throughput screening of cyclic peptides [1]. - Researchers designed and synthesized eight cyclic peptide sub-libraries, collectively forming a super library containing approximately 100 million different cyclic peptide molecules, utilizing various cyclization methods [2]. Group 2: Research Findings - In screening for the tumor-related protein MDM2, multiple sub-libraries exhibited a consistent enrichment pattern, with specific amino acid sequences showing high binding affinity, achieving a maximum binding activity (Ki) of 11 nM [2]. - The study revealed that some cyclic peptide combinations, which had low enrichment in single sub-libraries, demonstrated good activity after off-DNA synthesis, indicating that single sub-library screening may underestimate the potential of high-activity molecules [2]. Group 3: Specific Case Studies - For the GIT1 screening, no consistent enrichment pattern was observed across different sub-libraries, leading to the identification of two cyclic peptide compounds, one of which effectively blocked the interaction with β-PIX [3]. - The research emphasized the importance of using multiple methods, such as competitive screening and in vitro experiments, to comprehensively validate the authenticity and specificity of the screened compounds [3]. Group 4: Publication and Support - The research findings were published in JACS Au under the title "Influence of Macrocyclization Strategies on DNA-Encoded Cyclic Peptide Libraries," and the work received support from the National Natural Science Foundation of China [3].